American Healthcare REIT Inc’s filing revealed that its Director Streiff Mathieu B. acquired Company’s shares for reported $1.0 million on Feb 09 ’24. In the deal valued at $12.00 per share,83,333 shares were bought. As a result of this transaction, Streiff Mathieu B. now holds 90,740 shares worth roughly $1.27 million.
Then, Prosky Danny bought 83,333 shares, generating $999,996 in total proceeds. Upon buying the shares at $12.00, the CEO & President now owns 305,555 shares.
Barclays initiated its American Healthcare REIT Inc [AHR] rating to an Overweight in a research note published on March 14, 2024; the price target was $18. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering AHR with “an Outperform” recommendation on March 04, 2024. Morgan Stanley started covering the stock on March 04, 2024. It rated AHR as “an Overweight”.
Price Performance Review of AHR
On Tuesday, American Healthcare REIT Inc [NYSE:AHR] saw its stock fall -0.07% to $13.99. Over the last five days, the stock has gained 1.89%. American Healthcare REIT Inc shares have risen nearly 5.82% since the year began. A total of 0.67 million shares were traded, compared to the trading of 0.54 million shares in the previous session.
Levels Of Support And Resistance For AHR Stock
The 24-hour chart illustrates a support level at 13.89, which if violated will result in even more drops to 13.78. On the upside, there is a resistance level at 14.12. A further resistance level may holdings at 14.25. The Relative Strength Index (RSI) on the 14-day chart is 56.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 14.06%. Stochastics %K at 80.20% indicates the stock is a selling.
The most recent change occurred on March 04, 2024 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $16 price target.
